Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRESTIGE-AF

Financiado

Cerrado

PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrilla...

PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation Intracerebral hemorrhage (ICH) is a severe stroke subtype causing higher mortality and more disability than other strokes. 20% of ICH survivors have atrial fibrillation (AF), a major cause of ischemic stroke (IS). While IS in AF p... ver más

30/11/2024

IMPERIAL COLLEGE O...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND ME... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-11-30

SC1-PM-10-2017: Comparing the effectiveness of exis...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

IMPERIAL COLLEGE OF SCIENCE...

3.32M€ | Lider

KINGS COLLEGE LONDON

340.00K€ | Participante

UoB

4.55K€ | Participante

BELSPO

45.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CATCH ME Characterizing Atrial fibrillation by Translating its Causes... 5M€ Cerrado

EUTRAF The European Network for Translational Research in Atrial Fi... 16M€ Cerrado

ASAF Optimization of noninvasive assessment of the substrate for... 75K€ Cerrado

AFFECT-EU DIGITAL RISK BASED SCREENING FOR ATRIAL FIBRILLATION IN THE... 8M€ Cerrado

MMAF Novel multimodal approach to atrial fibrillation risk assess... 2M€ Cerrado

WAKE-UP Efficacy and safety of MRI based thrombolysis in wake up str... 16M€ Cerrado

Duración del proyecto: 83 meses Fecha Inicio: 2017-12-05
Fecha Fin: 2024-11-30

Líder del proyecto

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND ME... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Intracerebral hemorrhage (ICH) is a severe stroke subtype causing higher mortality and more disability than other strokes. 20% of ICH survivors have atrial fibrillation (AF), a major cause of ischemic stroke (IS). While IS in AF patients is generally prevented by oral anticoagulants (OAC), their use in ICH survivors is uncertain due to increased bleeding risk. No evidence from randomized controlled trials (RCT) is available addressing this dilemma. Personalized risk prediction is desirable to balance benefits of OAC against bleeding risk for individualized prevention. Objectives: (1) To perform the first sufficiently powered RCT in ICH survivors with AF testing if direct OAC are superior for IS prevention and non-inferior regarding ICH recurrence versus antiplatelet or no antithrombotic therapy (2) To personalize antithrombotic prevention by multidimensional risk modeling (3) To estimate population impact of trial outputs on health economic consequences and generalizability to European population (4) To explore patient-centered aspects including adherence, attitudes towards antithrombotic therapy and gender imbalances in trial enrollment. Methods: Prospective, open RCT with blinded outcome assessment. Hierarchical sequential testing of co-primary endpoint IS and recurrent ICH. Sample size expected: 314-420 patients. RCT will recruit in 70 centers in 6 countries over 4-5 years with a mean 2-year follow-up (minimum 6 months, maximum 36 months). Clinical characteristics, MRI, blood-biomarkers and genetics will be characterized at baseline to model a new personalized risk prediction tool. Relevance for work program: PRESTIGE-AF addresses the unmet need of best antithrombotic stroke prevention in ICH patients with AF. Recurrent stroke reduces individual life expectancy, quality of life and has high public health impact. Work packages integrating biological data will generate new tools to tailor prevention. Modeling of economic and societal consequences and replication in real-life settings will estimate population impact.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores